[High-dose gestagen therapy in breast cancer].
38 patients with metastasizing breast cancer who were stratified according to prognostic criteria were treated with high-dose medroxyprogesterone acetate (MPA). The response rate in our series was nearly 50 percent. The indication for high-dose gestagen therapy as well as anti-tumor activity and side effects are discussed by comparing our results with recent communications in the literature.
D000328:Adult; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy*; D002369:Castration; D004305:Dose-Response Relationship, Drug; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D012306:Risk; D012983:Soft Tissue Neoplasms / Q000556:secondary
D004965:Estrogen Antagonists; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone
Hochdosierte Gestagentherapie bei Mammakarzinom.